Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2007 Jul;66(7):849-51.
doi: 10.1136/ard.2007.069872.

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue

Ronald F van Vollenhoven
Editorial

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue

Ronald F van Vollenhoven. Ann Rheum Dis. 2007 Jul.

Abstract

The question of switching is not only a question of clinical practice, but has an important scientific dimension as well See linked article, p 893

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

References

    1. Van Vollenhoven R F, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) in patients who failed etanercept (Enbrel) or vice versa: data from the STURE registry showing that switching TNFα blockers can make sense. Ann Rheum Dis 2003621195–1198. - PMC - PubMed
    1. Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A.et al Switch étanercept—infliximab dans la polyarthrite rhumatoïde—14 patients sur 131 traités par anti‐TNFα. Presse Med 2002311836–1839. - PubMed
    1. Ang H T, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor‐alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003302315–2318. - PubMed
    1. Favalli E G, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S.et al Anti‐tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 200451301–302. - PubMed
    1. Hansen K E, Hildebrand J P, Genovese M C, Cush J J, Patel S, Cooley D A.et al The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004311098–1102. - PubMed

MeSH terms